Solara Active Pharma Sciences Limited has informed the Exchange regarding the following items approved at the Board meeting held on November 05, 2025.1. Appointment of Mr. Sarat Kumar, CFO as the Chief Investor Relations Officer2. Change in the remuneration of the Whole Time Director, Mr. Mohan Muthunarayanan3. Change in the remuneration of the eligible Senior Management Personnels.4. Review and confirmation of Risk Management Policy.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At a board meeting on November 05, 2025, Solara Active Pharma Sciences approved four items. The company's existing CFO, Mr. Sarat Kumar, has been given the additional role of Chief Investor Relations Officer. The board also approved a change in remuneration for Whole Time Director Mr. Mohan Muthunarayanan and for eligible Senior Management Personnel. Additionally, the board reviewed and confirmed the company's Risk Management Policy.
These are routine governance updates with no negative signals for shareholders. The CFO retaining his position while taking on investor relations duties signals continuity, while changes in director and senior management remuneration may marginally affect future financial expenses.